Publications by authors named "Eric Laille"

Claim this Profile
A
Azacitidine (Vidaza) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).
Alba Rubio-San-Simón, Natasha K A van Eijkelenburg, Raoull Hoogendijk, Henrik Hasle, Charlotte M Niemeyer, Eric J Laille

Paediatr Drugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Allison Gaudy, Eric Laille, Rochelle Bailey, Simon Zhou, Barry Skikne

Clin Pharmacol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Stéphane de Botton, Pau Montesinos, Andre C Schuh, Cristina Papayannidis, Paresh Vyas, Eric Laille

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, Uwe Platzbecker, Anna Jonasova, Eric Laille

J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly

Clin Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.
Hani M Babiker, Mohammed Milhem, Joseph Aisner, William Edenfield, Dale Shepard, Eric Laille

Cancer Chemother Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.
Hani M Babiker, Mohammed Milhem, Joseph Aisner, William Edenfield, Dale Shepard, Eric Laille

Cancer Chemother Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Marcos de Lima, Betul Oran, Richard E Champlin, Esperanza B Papadopoulos, Sergio A Giralt, Eric Laille

Biol Blood Marrow Transplant· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Michael R Savona, Kathryn Kolibaba, Paul Conkling, Edwin C Kingsley, Carlos Becerra, Eric Laille

Am J Hematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, Pamela N Munster, Jan H M Schellens, Eric Laille

Clin Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Xin Du, Yue-Yun Lai, Zhijian Xiao, Ting Liu, Yu Hu, Eric Laille

Asia Pac J Clin Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Dai Maruyama, Kensei Tobinai, Michinori Ogura, Toshiki Uchida, Kiyohiko Hatake, Eric Laille

Int J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
Wen-Chien Chou, Su-Peng Yeh, Liang-Tsai Hsiao, Sheng-Fung Lin, Yeu-Chin Chen, Eric Laille

Asia Pac J Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Eric Laille, Manish Patel, Suzanne F Jones, Howard A Burris, Jeffrey Infante

J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies.
Eric Laille, Michael R Savona, Bart L Scott, Thomas E Boyd, Qian Dong

J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
Eric Laille, Sanjay Goel, Alain C Mita, Nashat Y Gabrail, Kevin Kelly

Pharmacotherapy· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry.
Ellen J B Derissen, Michel J X Hillebrand, Hilde Rosing, Hans M M B Otten, Eric Laille

J Pharm Biomed Anal· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Guillermo Garcia-Manero, Steven D Gore, Christopher Cogle, Renee Ward, Tao Shi, Eric Laille

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.
Yong Chen, Lisa Liu, Eric Laille, Gondi Kumar, Sekhar Surapaneni

Cancer Chemother Pharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Eric Laille

Blood· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Lillian L Siu, Roberto Pili, Ignacio Duran, Wells A Messersmith, Eric X Chen, Eric J Laille

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles (Caretta caretta).
Elliott R Jacobson, Glenn R Harman, Lara K Maxwell, Eric J Laille

Am J Vet Res· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis